The role of IL-18 in type 1 diabetic nephropathy: The problem and future treatment |
| |
| Affiliation: | 1. Department of Clinical Biochemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt;2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia;1. Dept. of Endocrinology & Metabolism, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea;2. Dept. of Biomedical Laboratory Science, College of Health Sciences, Cheongju University, Cheongju, Chungbuk, 28503, Republic of Korea;1. Memorial Clinical Research, Oklahoma City, OK, United States;2. University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States;1. Medical School, University of Western Australia, Perth, Australia;2. Department of Nephrology, Prince of Wales Hospital, Sydney, Australia;3. Department of Nephrology, Sir Charles Gairdner Hospital, Perth, Australia;1. Clinical Epidemiology Center, VA Saint Louis Health Care System, St. Louis, Missouri, USA;2. Department of Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, Missouri, USA;3. Department of Medicine, Division of Nephrology, VA Saint Louis Health Care System, St. Louis, Missouri, USA;4. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA;1. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA;2. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA;3. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA;4. Hematology/Oncology Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;5. Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;6. Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA |
| |
| Abstract: | Diabetic vascular complication is a leading cause of diabetic nephropathy, a progressive increase in urinary albumin excretion coupled with elevated blood pressure leading to declined glomerular filtration and eventually end stage renal failure. There is growing evidence that activated inflammation is contributing factor to the pathogenesis of diabetic nephropathy. Meanwhile, IL-18, a member of the IL-1 family of inflammatory cytokines, is involved in the development and progression of diabetic nephropathy. However, the benefits derived from the current therapeutics for diabetic nephropathy strategies still provide imperfect protection against renal progression. This imperfection points to the need for newer therapeutic agents that have potential to affect primary mechanisms contributing to the pathogenesis of diabetic nephropathy. Therefore, the recognition of IL-18 as significant pathogenic mediators in diabetic nephropathy leaves open the possibility of new potential therapeutic targets. |
| |
| Keywords: | Type 1 diabetes mellitus Diabetic nephropathy Renal complications IL-18 IL-18 binding protein |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
